> INC Research has set terms for its planned $150 million IPO, expecting to sell 8.1 million shares at a range of $17 to $20 each. News
> As mid-sized CROs struggle to compete with their larger rivals, success increasingly depends on innovative business models, Mike Jagielski, CEO of KCR, tells Outsourcing-Pharma. More